Anifrolumab May Help Prevent Organ Damage in Patients With Systemic Lupus Erythematosus
Anifrolumab exhibited a high retention rate, effectively improved disease activity, and reduced glucocorticoid (GC) doses among patients with systemic lupus…
Anifrolumab exhibited a high retention rate, effectively improved disease activity, and reduced glucocorticoid (GC) doses among patients with systemic lupus…